Effect of metformin treatment on lipoprotein subfractions in non-diabetic patients with acute myocardial infarction: A glycometabolic intervention as adjunct to primary coronary intervention in st elevation myocardial infarction (GIPS-III) trial

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Eppinga, Ruben N ^a   Hartman, Minke H T ^a   Van Veldhuisen, Dirk J ^a   Lexis, Chris P H ^a   Connelly, Margery A ^b   Lipsic, Erik ^a   Van Der Horst, Iwan C C ^a   Van Der Harst, Pim ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADJUVANT CHEMOTHERAPY; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART STROKE VOLUME; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; APOLIPOPROTEINS; CHEMOTHERAPY, ADJUVANT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; COMBINED MODALITY THERAPY; CONVALESCENCE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPOPROTEINS; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PERCUTANEOUS CORONARY INTERVENTION; STROKE VOLUME; TRIGLYCERIDES;

EID: 85007250472     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145719     Document Type: Article

References (47)

1. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681. doi: 10.1016/S0140-6736(10)61350-5
2. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635-1701. doi: 10.1093/eurheartj/ehs092 PMID: 22555213
3. Kempen HJ, van Gent CM, Buytenhek R, Buis B. Association of cholesterol concentrations in low-density lipoprotein, high-density lipoprotein, and high-density lipoprotein subfractions, and of apolipoproteins AI and AII, with coronary stenosis and left ventricular function. J Lab Clin Med. 1987; 109: 19-26. PMID: 3098880
4. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 1998; 18: 1046-1053. PMID: 9672064
5. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002; 90: 89-94. PMID: 12106834
6. Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011; 57: 392-410. doi: 10.1373/clinchem.2010.155333 PMID: 21266551
7. Williams PT, Zhao X-Q, Marcovina SM, Brown BG, Krauss RM. Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PloS One. 2013; 8: e56782. doi: 10.1371/journal.pone.0056782 PMID: 23460815
8. Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis. 2014; 235: 585-591. doi: 10.1016/j.atherosclerosis.2014.05.914 PMID: 24956532
9. Joshi PH, Toth PP, Lirette ST, Griswold ME, Massaro JM, Martin SS, et al. Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. Eur J Prev Cardiol. 2014; doi: 10.1177/2047487314543890
10. Rosenson RS, Brewer HB, Rader DJ. Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. Circ Res. 2014; 114: 1880-1889. doi: 10.1161/CIRCRESAHA.114. 302805 PMID: 24902972
11. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2012; 60: 508-516. doi: 10.1016/j.jacc.2012.03.060 PMID: 22796256
12. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012; 125: 2469-2478. doi: 10.1161/CIRCULATIONAHA.111.073684 PMID: 22539783
13. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013; 128: 1189-1197. doi: 10.1161/ CIRCULATIONAHA.113.002671 PMID: 24002795
14. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011; 5: 105-113. doi: 10.1016/j.jacl.2011.02.001 PMID: 21392724
15. El Harchaoui K, van der Steeg WA, Stroes ESG, Kuivenhoven JA, Otvos JD, Wareham NJ, et al. Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007; 49: 547-553. doi: 10.1016/j.jacc.2006.09.043 PMID: 17276177
16. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy. Clin Lab Med. 2006; 26: 847-870. doi: 10.1016/j.cll.2006.07.006 PMID: 17110242
17. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009; 119: 931-939. doi: 10.1161/CIRCULATIONAHA.108. 816181 PMID: 19204302
18. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007; 192: 211-217. doi: 10.1016/j.atherosclerosis.2006.05.007 PMID: 16765964
19. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein Management in Patients With Cardiometabolic Risk Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008; 31: 811-822. doi: 10. 2337/dc08-9018 PMID: 18375431
20. Arsenault BJ, Després J-P, Stroes ESG, Wareham NJ, Kastelein JJP, Khaw K-T, et al. Lipid assessment, metabolic syndrome and coronary heart disease risk. Eur J Clin Invest. 2010; 40: 1081-1093. doi: 10.1111/j.1365-2362.2010.02357.x PMID: 20701625
21. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014; 129: 553-561. doi: 10.1161/ CIRCULATIONAHA.113.005873 PMID: 24345402
22. Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, et al. Lifestyle and Metformin Treatment Favorably Influence Lipoprotein Subfraction Distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013; 98: 3989-3998. doi: 10.1210/jc.2013-1452 PMID: 23979954
23. Preiss D, Lloyd SM, Ford I, McMurray JJ, Holman RR, Welsh P, et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2014; 2: 116-124. doi: 10.1016/S2213-8587(13)70152-9 PMID: 24622715
24. Trifunovic D, Stankovic S, Sobic-Saranovic D, Marinkovic J, Petrovic M, Orlic D, et al. Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function. Cardiovasc Diabetol. 2014; 13: 73. doi: 10.1186/1475-2840-13-73 PMID: 24708817
25. Sanjuan R, Blasco ML, Huerta R, Palacios L, Carratala A, Nunyez J, et al. Insulin resistance and shortterm mortality in patients with acute myocardial infarction. Int J Cardiol. 2014; 172: e269-270. doi: 10. 1016/j.ijcard.2013.12.207 PMID: 24485226
26. Lexis CPH, van der Horst ICC, Lipsic E, van der Harst P, van der Horst-Schrivers ANA, Wolffenbuttel BHR, et al. Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial. Cardiovasc Drugs Ther Spons Int Soc Cardiovasc Pharmacother. 2012; 26: 417-426. doi: 10.1007/s10557-012-6413-1
27. Lexis CPH, van der Horst ICC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AFM, et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA. 2014; 311: 1526-1535. doi: 10.1001/jama.2014.3315 PMID: 24687169
28. Oksala N, Seppälä I, Hernesniemi J, Lyytikäinen L-P, Kähönen M, Mäkelä K-M, et al. Complementary prediction of cardiovascular events by estimated apo- and lipoprotein concentrations in the working age population. The Health 2000 Study. Ann Med. 2012; 45: 141-148. doi: 10.3109/07853890.2012. 679962 PMID: 22524251
29. Wong DTL, Richardson JD, Puri R, Nelson AJ, Bertaso AG, Teo KSL, et al. The role of cardiac magnetic resonance imaging following acute myocardial infarction. Eur Radiol. 2012; 22: 1757-1768. doi: 10.1007/s00330-012-2420-7 PMID: 22447378
30. Van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998; 97: 2302-2306. PMID: 9639373
31. Avogaro P, Bon GB, Cazzolato G, Quinci GB, Sanson A, Sparla M, et al. Variations in apolipoproteins B and A, during the course of myocardial infarction. Eur J Clin Invest. 1978; 8: 121-129.
32. Bouma M, Rutten FH, Wiersma T, Burgers JS. [Revised Dutch College of General Practitioners' practice guideline "Acute coronary syndrome"]. Ned Tijdschr Geneeskd. 2013; 157: A6006. PMID: 23425721
33. Riemens SC, van Tol A, Scheek LM, Dullaart RP. Plasma cholesteryl ester transfer and hepatic lipase activity are related to high-density lipoprotein cholesterol in association with insulin resistance in type 2 diabetic and non-diabetic subjects. Scand J Clin Lab Invest. 2001; 61: 1-9.
34. Brunner MP, Shah SH, Craig DM, Stevens RD, Muehlbauer MJ, Bain JR, et al. Effect of heparin administration on metabolomic profiles in samples obtained during cardiac catheterization. Circ Cardiovasc Genet. 2011; 4: 695-700. doi: 10.1161/CIRCGENETICS.111.960575 PMID: 22010138
35. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet Lond Engl. 2007; 370: 1829-1839.
36. The Emerging Risk Factors Collaboration∗. MAjor lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302: 1993-2000. doi: 10.1001/jama.2009.1619 PMID: 19903920
37. Xu R-X, Li S, Li X-L, Zhang Y, Guo Y-L, Zhu C-G, et al. High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. J Clin Lipidol. 2015; 9: 26-34. doi: 10.1016/j.jacl.2014.11.003 PMID: 25670357
38. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005; 26: 890-896. doi: 10.1093/eurheartj/ ehi186 PMID: 15764620
39. Dullaart RPF, Tietge UJF, Kwakernaak AJ, Dikkeschei BD, Perton F, Tio RA. Alterations in plasma lecithin: cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: implications for cardiac outcome. Atherosclerosis. 2014; 234: 185-192. doi: 10.1016/j.atherosclerosis.2014.02.026 PMID: 24661908
40. Dullaart RPF, Annema W, Tio RA, Tietge UJF. The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol. Clin Chim Acta Int J Clin Chem. 2014; 433: 34-38. doi: 10.1016/j.cca.2014.02.026
41. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364: 127-135. doi: 10.1056/NEJMoa1001689 PMID: 21226578
42. Triolo M, Annema W, Dullaart RPF, Tietge UJF. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark Med. 2013; 7: 457-472. doi: 10. 2217/bmm.13.35 PMID: 23734809
43. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation. 2009; 120: 2345-2351.
44. Gordts SC, Muthuramu I, Nefyodova E, Jacobs F, Van Craeyveld E, De Geest B. Beneficial effects of selective HDL-raising gene transfer on survival, cardiac remodelling and cardiac function after myocardial infarction in mice. Gene Ther. 2013; 20: 1053-1061. doi: 10.1038/gt.2013.30 PMID: 23759702
45. Tardif J-C, Ballantyne CM, Barter P, Dasseux J-L, Fayad ZA, Guertin M-C, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014; 35: 3277-3286. doi: 10.1093/eurheartj/ehu171 PMID: 24780501
46. Yang N, Feng J-P, Chen G, Kou L, Li Y, Ren P, et al. Variability in lipid profile among patients presented with acute myocardial infarction, unstable angina and stable angina pectoris. Eur Rev Med Pharmacol Sci. 2014; 18: 3761-3766. PMID: 25555864
47. Fujino M, Ishihara M, Honda S, Kawakami S, Yamane T, Nagai T, et al. Impact of acute and chronic hyperglycemia on in-hospital outcomes of patients with acute myocardial infarction. Am J Cardiol. 2014; 114: 1789-1793. doi: 10.1016/j.amjcard.2014.09.015 PMID: 25438903